STRO (Sutro Biopharma) PB Ratio: (As of Jul. 13, 2026)


STRO Sutro Biopharma Inc STRO
45 GF Score
Price $29.71
GF Value $12.04
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-13), Sutro Biopharma's share price is $29.71. Sutro Biopharma's Book Value per Share for the quarter that ended in Mar. 2026 was $-4.04. Hence, Sutro Biopharma's PB Ratio of today is .

The historical rank and industry rank for Sutro Biopharma's PB Ratio or its related term are showing as below:

During the past 10 years, Sutro Biopharma's highest PB Ratio was 3.82. The lowest was 0.82. And the median was 1.99.

STRO's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.93
* Ranked among companies with meaningful PB Ratio only.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Sutro Biopharma was -1.80% per year. The lowest was -53.70% per year. And the median was -17.00% per year.

Back to Basics: PB Ratio


Sutro Biopharma  (NAS:STRO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Sutro Biopharma PB Ratio Related Terms


Sutro Biopharma PB Ratio Historical Data

* Premium members only.

The historical data trend for Sutro Biopharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sutro Biopharma PB Ratio Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.73 2.14 1.75 3.40 0.00

Sutro Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STRO vs NGNE, OCGN, CBIO: PB Ratio Comparison

For the Biotechnology subindustry, Sutro Biopharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sutro Biopharma PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's PB Ratio falls into.


STRO
45GF Score
Sutro Biopharma Inc STRO
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sutro Biopharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Sutro Biopharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=29.71/-4.037
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Sutro Biopharma (STRO) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of $29.71 is trading 146.8% above its estimated GF Value™ of $12.04. GuruFocus considers Sutro Biopharma to be Significantly Overvalued.

Key valuation signals for STRO:

  • PB Ratio:
  • GF Value™: $12.04 vs. price of $29.71 (146.8% above fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the STRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sutro Biopharma Business Description

Other Exchanges S090:Germany
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score

Get the complete analysis for STRO

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.71
Price
$12.04
GF Value